In production systems today, most AI agents operate as lightweight dispatchers. They parse a prompt, make an API call, retrieve a record, and hand back control. Their execution is fast, stateless and cheap. Biotechnology does not work this way.
Folding a protein target, screening a 50,000 compound ligand library, or evaluating structure-activity relationships (SAR) are not quick API lookups. They are sustained, stateful, GPU-bound simulations that run for minutes or even hours across specialized silicon. When you ask a general-purpose large language model (LLM) endpoint to coordinate a complex drug discovery workflow, the standard paradigm breaks: Timeouts occur, context windows overflow with atomic coordinates, and proprietary chemical Intellectual Property (IP) risks exposure to external networks.
Building enterprise grade research and development (R&D) agents requires moving past the monolithic assistant model. In this blog post, we will discuss how to use a three-layer architecture: separating cognitive orchestration (the brain) from computational execution (the muscle), and anchoring both inside an enterprise governance plane to build scalable agents for drug discovery use cases in biotech.
The reference architecture below shows how to architect, optimize, and govern high-compute autonomous agents in biotechnology, specifically Drug Discovery.
Figure 1 — The three-layer pattern: a cognitive orchestrator (brain), a scalable GPU execution layer (muscle), and an enterprise governance plane.
The execution layer is responsible for the heavy scientific computations. The first architectural decision is determining where workloads should run:
Strategic, proprietary pipelines require dedicated GPU infrastructure within your security perimeter
Routine or standardized workloads can safely be delegated to managed cloud endpoints
In this architecture, protein folding is driven by ESMFold and generative design by GenMol. Both run as NVIDIA Inference Microservices or NIMs deployed on Google Kubernetes Engine (GKE) using G4 VMs backed by NVIDIA RTX PRO 6000 Blackwell GPUs.
A critical hurdle in containerized GPU workloads is the cold-start penalty, the latency delay required to pull multi-gigabyte model weights from an image registry and stage them into GPU memory (VRAM).
To ensure low latency responsiveness, we build the following as a recommendation into the reference architecture:
Maintain warm pools: Pin the GKE node pool to a minimum of one active node.
Preload weights: Model weights are loaded directly into VRAM at pod initialization, ensuring containers are immediately ready for inference.
Resilient scheduling: GKE manages pod lifecycles and restarts failed instances without tearing down the underlying VM infrastructure.
This approach trades custom, manual CUDA kernel tuning for NVIDIA’s pre-compiled, containerized runtimes, dramatically reducing infrastructure engineering overhead while ensuring deterministic throughput.
In biotech, chemical structures represent millions of dollars in proprietary IP. A docking request transmits SMILE strings or 3D coordinate matrices that must never leave company custody.
Containerized NIMs eliminate the friction between rapid prototyping and rigorous data isolation. During early exploration, researchers can query NVIDIA hosted endpoints. When transitioning to proprietary lead candidates, the exact same container is deployed to GKE inside a private VPC. The agent’s orchestration logic remains identical; only the target URI updates from an external proxy to an internal VPC endpoint. No structural data leaves the enterprise perimeter.
With compute execution isolated, the cognitive layer manages agentic workflow sequencing. Built on Agent Runtime, within the Gemini platform, this reference architecture shows a system that deploys a hierarchical multi-agent structure, one lead orchestrator, and two specialized domain sub-agents (Lead Optimization and Safety Screening) . The multi-agent design can be modified to suit the use case at hand.
Based on this design, when an end-user submits a high-level task such as “ Analyze Candidate 4b against Target X and produce a SAR report”, the system applies four core orchestration patterns discussed below;
By passing disease context directly into the specialized reasoning models, drug candidates are evaluated against dynamic, target-specific profiles rather than static thresholds, preventing the premature culling of viable drug leads.
Optimizing an agentic system that interfaces with heavy GPU compute requires challenging common engineering instincts:
| Common Assumption | Architectural Reality | Recommended Best Practice |
| “Swap in a faster driver model to cut latency.” | The primary orchestrator’s token generation is rarely the bottleneck in multi-step R&D pipelines. | Optimize I/O, not token speed: Focus on reducing payload sizes and intermediate network hops rather than compromising orchestrator reasoning depth. |
| “Parallelize tool calls across workers.” | External scientific services and containerized models often serialize requests internally on dedicated hardware. | Respect execution topology: Align client-side concurrency with backend queue mechanics to prevent pipeline lockouts and connection timeouts. |
| “Pass full simulation states between tools.” | Large JSON bodies cause schema validation failures, prompt truncation, and token bloat. | Pass heavy payloads by reference: Store raw coordinates in object storage and pass lightweight URIs between agent boundaries. |
| “Return outputs only when the pipeline finishes.” | Long multi-minute runs leave scientists blind to whether jobs are proceeding or stalled. | Stream intermediate stage completions: Emit progress updates at each completed milestone (e.g., folding complete, docking running) for real-time visibility. |
| “Chain multiple granular micro-tools.” | Deep tool-chains increase the probability of hallucinated arguments and schema mismatches. | Collapse compute pipelines: Wrap end-to-end simulation pipelines behind a single, clean tool interface that takes clear parameters and returns a consolidated object. |
Deploying high-compute agents in enterprise environments requires robust data sovereignty, audit trails, and process control. The Gemini platform establishes these safeguards natively with the following components:
Agent Identity: Every autonomous agent operates with a cryptographically verifiable identity. Thus, for a biotech use case, when a candidate molecule is advanced or rejected, the event is permanently logged to that specific agent principal.
Agent Gateway: This serves the single ingress/egress point for every interaction within the perimeter. Centralized IAM and regional residency rules help ensure sensitive molecular data remains within designated cloud regions.
Agent Registry: This feature maintains a curated catalog of approved agents, validated tool schemas, and authorized Model Context Protocol (MCP) servers, preventing rogue tools from executing in production.
Model Armor: This functionality inspects incoming prompts and outgoing payloads in real time to prevent prompt injection and data exfiltration.
The payoff is clear. Identity, RBAC, auditing, residency, and data protection are native properties of the Gemini platform; this allows enterprise customers to focus on science rather than having to build a compliance stack for every project.
In high-stakes research and development, full autonomy introduces unacceptable liability, while requiring approval for trivial steps can create frictions. The solution addressing this to use asymmetric gating in the following ways;
Automate reversible operations: For example, allow the agent to resolve chemical naming synonyms, pull structural PDBs, and run preliminary Lipinski screens autonomously without interrupting the researcher.
Gate irreversible operations: For instance, initiating multi-GPU docking run, advancing a lead compound to wet-lab synthesis, or archiving a therapeutic program must require explicit human sign-off.
High-compute autonomous agents succeed when the boundaries between cognitive planning, numerical computation, and system governance are clean in the following ways:
Keep the orchestrator focused on decomposition and synthesis, leaving intensive biophysical simulation to specialized, containerized microservices and models.
Eliminate context bloat by passing complex chemical data by reference through cloud storage.
Anchor the workflow in enterprise governance, pairing cryptographic agent identity with asymmetric human oversight.
As generative and structural biology models expand toward whole-cell modeling and complex dynamic simulations, this decoupled architecture ensures research systems scale efficiently while keeping proprietary IP secure and auditable.
Reach out to your Google sales representative if you have any requirements to build a use case like this and we will be happy to talk and support you in your agent development journey on Google Cloud.
Prasanna Vijayanathan, Renzo Sanchez-SilvaWhen Jake Paul and Mike Tyson stepped into the ring in November…
The North Star Every organization racing to deploy AI agents faces the same reckoning: an…
The metric might not mean much to laypeople, but leap seconds have been a source…
Information about food properties that determine quality, safety and sensory characteristics is critical for food…